Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
372.00
-1.46 (-0.39%)
Aug 14, 2025, 9:33 AM - Market open
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Madrigal Pharmaceuticals stock ranges from a low of $350 to a high of $523. The average analyst price target of $439.71 forecasts a 18.20% increase in the stock price over the next year.
Price Target: $439.71 (+18.20%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 5 | 5 | 5 | 5 |
| Buy | 6 | 4 | 4 | 4 | 4 | 2 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 9 | 10 | 10 | 10 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $458 → $523 | Strong Buy | Maintains | $458 → $523 | +40.59% | Aug 12, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $420 → $428 | Strong Buy | Maintains | $420 → $428 | +15.05% | Aug 6, 2025 |
| UBS | UBS | Strong Buy Maintains $441 → $458 | Strong Buy | Maintains | $441 → $458 | +23.12% | May 2, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $422 → $460 | Strong Buy | Reiterates | $422 → $460 | +23.66% | May 2, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $394 → $420 | Strong Buy | Maintains | $394 → $420 | +12.90% | May 2, 2025 |
Financial Forecast
Revenue This Year
696.52M
from 180.13M
Increased by 286.67%
Revenue Next Year
1.17B
from 696.52M
Increased by 67.98%
EPS This Year
-13.54
from -21.90
EPS Next Year
0.65
from -13.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 827.8M | 1.6B | 2.2B | ||
| Avg | 696.5M | 1.2B | 1.8B | ||
| Low | 587.5M | 862.7M | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 359.5% | 123.5% | 88.0% | ||
| Avg | 286.7% | 68.0% | 54.7% | ||
| Low | 226.1% | 23.9% | -1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.18 | 20.31 | 36.67 | ||
| Avg | -13.54 | 0.65 | 18.79 | ||
| Low | -19.54 | -12.23 | -1.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 5,562.8% | ||
| Avg | - | - | 2,801.2% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.